Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours ยท Estimated delivery Aug 24 - Aug 29
The DSIP is a preselected, diversified, regularly reviewed list of stocks with attractive yields and are likely to consistently raise their annual dividends
Article 11 mins A Surge in Gene and Cell Therapies Raises Financing Questions Gene and cell therapies represent breakthrough advances in medicine, but they also have significant costs and potential risks for patients, employers, insurers, governments and manufacturers
In 2024, Ozempic was the third-best-selling drug in the country, with sales growing by 25 percent from 2023, which had already been a blockbuster year, with nearly $40 billion in sales
Providing GLP-1 drugs to 19.7 million Medicare beneficiaries with obesity would cost $268 billion a year, researchers estimate in a recent study
Recent studies have raised concerns about a higher risk of gastroparesis in GLP-1 medication users
US$ 27.24
US$ 20.38
US$ 29.27
US$ 27.20
